CO5540375A2 - Una combinacion farmaceutica que comprende uno cualquiera de acido (s)-2-etoxi-3-(4-(2-(4-metanosulfoniloxifenil) etoxi) fenil)propanoico o acido 3-(4-(2-(4-tert- butoxicarbonilaminofenil)etoxi)fenil)-(s)-2-etoxi propanoico y un farmaco de biguanida - Google Patents
Una combinacion farmaceutica que comprende uno cualquiera de acido (s)-2-etoxi-3-(4-(2-(4-metanosulfoniloxifenil) etoxi) fenil)propanoico o acido 3-(4-(2-(4-tert- butoxicarbonilaminofenil)etoxi)fenil)-(s)-2-etoxi propanoico y un farmaco de biguanidaInfo
- Publication number
- CO5540375A2 CO5540375A2 CO03112108A CO03112108A CO5540375A2 CO 5540375 A2 CO5540375 A2 CO 5540375A2 CO 03112108 A CO03112108 A CO 03112108A CO 03112108 A CO03112108 A CO 03112108A CO 5540375 A2 CO5540375 A2 CO 5540375A2
- Authority
- CO
- Colombia
- Prior art keywords
- etoxi
- phenyl
- ethoxy
- propanoic
- acid
- Prior art date
Links
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 2
- 239000002253 acid Substances 0.000 title 2
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000012453 solvate Substances 0.000 abstract 4
- 229960003105 metformin Drugs 0.000 abstract 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 3
- QNDFBOXBUCDYNZ-NRFANRHFSA-N (2s)-2-ethoxy-3-[4-[2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]ethoxy]phenyl]propanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(NC(=O)OC(C)(C)C)C=C1 QNDFBOXBUCDYNZ-NRFANRHFSA-N 0.000 abstract 2
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 abstract 2
- -1 2- {4- methanesulfonyloxyphenyl} ethoxy Chemical group 0.000 abstract 1
- 229940123208 Biguanide Drugs 0.000 abstract 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Abstract
1.- Una combinación farmacéutica que comprende uno cualquiera de ácido (S)-2-etoxi-3-[4-(2-{4-metanosulfoniloxifenil)etoxi)fenil] propanoico o ácido 3-{4-[2-(4-tert-butoxicarbonilaminofenil)etoxi]fenil)-(S)-2-etoxi propanoico, o una sal farmacéuticamente aceptable de los mismos y solvatos cualesquiera de uno cualquiera de los mismos y un fármaco de biguanida.2.- Una combinación farmacéutica de acuerdo con reivindicación 1 que comprende ácido (S)-2-etoxi-3-[4-(2-{4-metanosulfoniloxifenil}etoxi)fenil] propanoico o una sal farmacéuticamente aceptable del mismo o solvatos de uno cualquiera de los mismos y metformina.3.- Una combinación farmacéutica de acuerdo con reivindicación 1 que comprende ácido 3-{4-[2-(4-tert-butoxicarbonilaminofenil)etoxi]fenil}-(S)-2-etoxi propanoico o una sal farmacéuticamente aceptable del mismo y solvatos cualesquiera de uno cualquiera de los mismos y metformina.4.- Una combinación farmacéutica que comprende ácido (S)-2-etoxi-3-[4- (2- {4- metanosulfoniloxifenil}etoxi) fenil] propanoico o 3- {4-[2-(4-tert-butoxicarbonilaminofenil)etoxi]fenil}-(S)-2-etoxi propanoico o una sal farmacéuticamente aceptable del mismo y solvatos cualesquiera de uno cualquiera de los mismos y metformina con un portador y/o diluyente farmacéuticamente aceptables.5.- Un método de tratar o prevenir diabetes que comprende administrar a un paciente una cantidad efectiva de una combinación farmacéutica como se define en la reivindicación 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0101980A SE0101980D0 (sv) | 2001-06-01 | 2001-06-01 | Pharmaceutical combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5540375A2 true CO5540375A2 (es) | 2005-07-29 |
Family
ID=20284362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO03112108A CO5540375A2 (es) | 2001-06-01 | 2003-12-23 | Una combinacion farmaceutica que comprende uno cualquiera de acido (s)-2-etoxi-3-(4-(2-(4-metanosulfoniloxifenil) etoxi) fenil)propanoico o acido 3-(4-(2-(4-tert- butoxicarbonilaminofenil)etoxi)fenil)-(s)-2-etoxi propanoico y un farmaco de biguanida |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20040152771A1 (es) |
| EP (2) | EP1666034A1 (es) |
| JP (1) | JP2004532864A (es) |
| KR (1) | KR20040008202A (es) |
| CN (1) | CN1535144A (es) |
| AT (1) | ATE336993T1 (es) |
| BR (1) | BR0210128A (es) |
| CA (1) | CA2448643A1 (es) |
| CO (1) | CO5540375A2 (es) |
| CZ (1) | CZ20033234A3 (es) |
| DE (1) | DE60214185T2 (es) |
| EE (1) | EE200300584A (es) |
| ES (1) | ES2269686T3 (es) |
| HK (1) | HK1062813A1 (es) |
| HU (1) | HUP0400946A3 (es) |
| IL (1) | IL159033A0 (es) |
| IS (1) | IS7058A (es) |
| MX (1) | MXPA03011005A (es) |
| NO (1) | NO20035237D0 (es) |
| PL (1) | PL367891A1 (es) |
| RU (1) | RU2003136154A (es) |
| SE (1) | SE0101980D0 (es) |
| SK (1) | SK14702003A3 (es) |
| WO (1) | WO2002096402A1 (es) |
| ZA (1) | ZA200309264B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201636015A (zh) * | 2013-07-05 | 2016-10-16 | 卡地拉保健有限公司 | 協同性組成物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
| US6552055B2 (en) * | 1996-12-11 | 2003-04-22 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
| US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
| SE9801990D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl propionic acid derivatives and analogs |
| SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
| ATE266409T1 (de) * | 2000-04-13 | 2004-05-15 | Pfizer Prod Inc | Synergistische wirkung von glyburide und milrinone |
-
2001
- 2001-06-01 SE SE0101980A patent/SE0101980D0/xx unknown
-
2002
- 2002-05-30 EP EP06000170A patent/EP1666034A1/en not_active Withdrawn
- 2002-05-30 WO PCT/SE2002/001038 patent/WO2002096402A1/en not_active Application Discontinuation
- 2002-05-30 EE EEP200300584A patent/EE200300584A/xx unknown
- 2002-05-30 RU RU2003136154/15A patent/RU2003136154A/ru not_active Application Discontinuation
- 2002-05-30 MX MXPA03011005A patent/MXPA03011005A/es unknown
- 2002-05-30 US US10/478,798 patent/US20040152771A1/en not_active Abandoned
- 2002-05-30 HU HU0400946A patent/HUP0400946A3/hu unknown
- 2002-05-30 CA CA002448643A patent/CA2448643A1/en not_active Abandoned
- 2002-05-30 BR BR0210128-9A patent/BR0210128A/pt not_active IP Right Cessation
- 2002-05-30 CZ CZ20033234A patent/CZ20033234A3/cs unknown
- 2002-05-30 PL PL02367891A patent/PL367891A1/xx not_active Application Discontinuation
- 2002-05-30 CN CNA028149394A patent/CN1535144A/zh active Pending
- 2002-05-30 AT AT02728300T patent/ATE336993T1/de not_active IP Right Cessation
- 2002-05-30 SK SK1470-2003A patent/SK14702003A3/sk not_active Application Discontinuation
- 2002-05-30 ES ES02728300T patent/ES2269686T3/es not_active Expired - Lifetime
- 2002-05-30 EP EP02728300A patent/EP1404309B1/en not_active Expired - Lifetime
- 2002-05-30 JP JP2002592913A patent/JP2004532864A/ja not_active Withdrawn
- 2002-05-30 KR KR10-2003-7015601A patent/KR20040008202A/ko not_active Application Discontinuation
- 2002-05-30 IL IL15903302A patent/IL159033A0/xx unknown
- 2002-05-30 DE DE60214185T patent/DE60214185T2/de not_active Expired - Fee Related
-
2003
- 2003-11-25 NO NO20035237A patent/NO20035237D0/no not_active Application Discontinuation
- 2003-11-27 ZA ZA200309264A patent/ZA200309264B/en unknown
- 2003-11-28 IS IS7058A patent/IS7058A/is unknown
- 2003-12-23 CO CO03112108A patent/CO5540375A2/es not_active Application Discontinuation
-
2004
- 2004-08-02 HK HK04105673A patent/HK1062813A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60214185D1 (en) | 2006-10-05 |
| BR0210128A (pt) | 2004-06-08 |
| HK1062813A1 (en) | 2004-11-26 |
| HUP0400946A3 (en) | 2007-11-28 |
| WO2002096402A1 (en) | 2002-12-05 |
| EP1666034A1 (en) | 2006-06-07 |
| EE200300584A (et) | 2004-02-16 |
| CN1535144A (zh) | 2004-10-06 |
| EP1404309B1 (en) | 2006-08-23 |
| MXPA03011005A (es) | 2004-02-27 |
| SK14702003A3 (sk) | 2004-09-08 |
| ES2269686T3 (es) | 2007-04-01 |
| NO20035237D0 (no) | 2003-11-25 |
| SE0101980D0 (sv) | 2001-06-01 |
| EP1404309A1 (en) | 2004-04-07 |
| ZA200309264B (en) | 2005-02-28 |
| CZ20033234A3 (cs) | 2004-12-15 |
| ATE336993T1 (de) | 2006-09-15 |
| JP2004532864A (ja) | 2004-10-28 |
| US20040152771A1 (en) | 2004-08-05 |
| HUP0400946A2 (hu) | 2004-08-30 |
| PL367891A1 (en) | 2005-03-07 |
| KR20040008202A (ko) | 2004-01-28 |
| IS7058A (is) | 2003-11-28 |
| DE60214185T2 (de) | 2007-07-19 |
| CA2448643A1 (en) | 2002-12-05 |
| IL159033A0 (en) | 2004-05-12 |
| RU2003136154A (ru) | 2005-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU93043528A (ru) | Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения | |
| PE83199A1 (es) | Composicion farmaceutica de tiazolidinadiona y biguanida para el tratamiento de la diabetes | |
| NO20044534L (no) | Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer | |
| BR0113710A (pt) | Compostos, processo para a preparação e utilização dos mesmos, composição farmacêutica, processo para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, insuficiência renal, distúrbios alimentares e obesidade | |
| DK2316831T3 (da) | 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer | |
| BR9910913A (pt) | Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, e, processo para a profilaxia e/ou tratamento de condições clìnicas associadas com resistência a insulina | |
| GT199700042A (es) | Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil) etil)-6-cloro-1,3-dihidro-2h-indol-2-ona | |
| AR042511A1 (es) | Intermedio de formulacion no higroscopico que comprende un farmaco higroscopico | |
| ES2150663T3 (es) | Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina. | |
| ME00318B (me) | Nova kompozicija i njena upotreba | |
| ATE408593T1 (de) | Pyruvatderivate | |
| NO20011351L (no) | Fremgangsmåte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav | |
| AR029412A1 (es) | Forma cristalina | |
| DK0381514T3 (da) | Anvendelse af N-methyl-sphingosin som inhibitor for cellevækst | |
| DK149852C (da) | Analogifremgangsmaade til fremstilling af substituerede 3-aminosydnoniminer eller et farmakologisk acceptabelt syreadditionssalt deraf | |
| CO5540375A2 (es) | Una combinacion farmaceutica que comprende uno cualquiera de acido (s)-2-etoxi-3-(4-(2-(4-metanosulfoniloxifenil) etoxi) fenil)propanoico o acido 3-(4-(2-(4-tert- butoxicarbonilaminofenil)etoxi)fenil)-(s)-2-etoxi propanoico y un farmaco de biguanida | |
| KR910007531A (ko) | 15-케토-프로스타글란딘 화합물을 이용한 간 담즙성 질병의 치료 | |
| NO305082B1 (no) | 2-(4-(4-azolbutyl)-1-piperazinyl)-5-hydroksy-pyrimidinderivater, deres fremstilling og anvendelse som legemidler | |
| AR026704A1 (es) | Forma cristalina | |
| AP9901474A0 (en) | Pharmaceutical composition for treating viral diseases. | |
| PE89199A1 (es) | Composicion farmaceutica de tiazolidinadiona y un inhibidor de alfa glucosidasa para el tratamiento de la diabetes | |
| DK0378146T3 (da) | Polyamin-derivater som antineoplastiske midler | |
| CO4960663A1 (es) | Fumarato de 2-(-3-(4-(2-t-butil-6-trifluorometilpirimidin- 4-il)piperazin-1-il) propilmecapto)pirimidin-4-ol | |
| CO5540383A2 (es) | UNA COMBINACION FARMACEUTICA QUE COMPRENDE UNO CUALQUIERA DE ACIDO (S)-2-ETOXI-3-(4-(2-(4-METANOSULFONIL OXIFENIL) ETOXI)FENIL) PROPANOICO O ACIDO 3-(4-(2-(4-TERT-BUTOXI CARBONIL-AMINOFENIL)ETOXI)FENIL)-(s)-2-ETOXI PROPANOICO E INSULINA | |
| ATE44875T1 (de) | 4-amino-2-(imidazolidin-2-on-l-yl)-pyrimidin-5carbons|ure-(n-(3-trifluormethyl-phenyl)-amide) zur antithrombotischen prophylaxe und behandlung sowie ihre verwendung zur herstellung von antithrombotisch wirksamen arzneimitteln. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |